Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:

Advertisements

Similar presentations

Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors F Zerbib, A Duriez, S Roman, M.

Advertisements

Figure 3 Low-grade inflammation in FGID

Figure 2 Enteroids can model transport physiology

Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 4 Activation of clopidogrel via cytochrome P450

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 1 Patients cured of HCV infection

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Michael F. Vaezi, David Katzka, Frank Zerbib

Figure 3 Algorithm from working group describing

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Schematic outlining the results of Buffington et al.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Host range of hepatitis E virus

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Pseudorelaxation as a consequence of

Figure 1 Environmental factors contributing to IBD pathogenesis

Figure 4 Examples of reflux episodes on pH and pH-impedance monitoring

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

Figure 4 Functional luminal imaging probe

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 High-resolution manometry studies performed

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Figure 5 PPIs and adverse events with proven and unproven causality

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 8 Assessment of colonic tone using a barostat device

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence.

Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.50 Figure 1 Current treatment algorithm for patients with typical GERD symptoms Figure 1 | Current treatment algorithm for patients with typical GERD symptoms. Investigation of patients with rGERD symptoms is centred around multichannel intraluminal impedance (MII)–pH monitoring. *Before rGERD can be considered, one should ensure that the PPI regimen is adequately dosed and timed, that patient compliance with the regimen is confirmed, and that symptoms are typical of GERD (heartburn and/or regurgitation) and are not located in the epigastrium (dyspepsia) or in the throat area. rGERD, refractory GERD. Scarpellini, E. et al. (2016) Management of refractory typical GERD symptoms Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.50